Mounjaro vs Ozempic: head-to-head results, doses, side effects and cost
Mounjaro® contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Ozempic® contains semaglutide, a GLP-1 receptor agonist.1,2 Each is injected once a week and is FDA-approved to treat type 2 diabetes, not to treat weight. The single large head-to-head trial, SURPASS-2, found that all three Mounjaro doses brought A1C and weight down further than Ozempic 1 mg across 40 weeks.3 Below are the numbers, that trial’s limits, and how doses, side effects and prices compare.
Key points
- Different drugs. Tirzepatide (Eli Lilly) targets two receptors. Semaglutide (Novo Nordisk) targets one.
- Same approved use. Both treat type 2 diabetes. Zepbound® and Wegovy® are the weight management versions.
- Head to head. SURPASS-2 averages: 16.8 to 24.7 lb lost with Mounjaro, 12.6 lb with Ozempic 1 mg.
- Limits. Ozempic 2 mg was not tested, and only Ozempic has a kidney indication and a tablet.
Mounjaro and Ozempic: what is the difference?
The difference is the molecule. Tirzepatide, the drug in Mounjaro, is one compound that switches on receptors for two gut hormones. Semaglutide, the drug in Ozempic, is a close copy of human GLP-1 and works through that receptor only.1,2 Either one prompts insulin release when blood sugar is high, slows stomach emptying and reduces appetite.2,4 For the basics, read what GLP-1 means.
| Feature | Mounjaro | Ozempic |
|---|---|---|
| Drug class | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Generic name | Tirzepatide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA-approved uses | Type 2 diabetes from age 10, plus cardiovascular risk reduction for high-risk adults who have it | Type 2 diabetes in adults, plus cardiovascular and kidney risk reduction for adults who have those conditions too |
| Weight loss approval | None. Zepbound holds it for tirzepatide | None. Wegovy holds it for semaglutide |
| Form | Weekly injection | Weekly injection, or a daily tablet |
| Dose range | 2.5 to 15 mg weekly | 0.25 to 2 mg weekly |
| Cash price from the maker | $499 a month and up | $349 a month, or $499 for 2 mg |
Uses and doses: prescribing information.1,2 Prices: the manufacturers, as of November 2026.5,6
Mounjaro vs Ozempic for weight loss
People taking Mounjaro lost more weight than people taking Ozempic in the one large trial of both. Neither drug is approved for weight loss, so prescribing it only for weight is off-label.1,2
SURPASS-2: Mounjaro against Ozempic 1 mg
The trial enrolled 1,879 people. All had type 2 diabetes and took metformin, and each spent 40 weeks on Mounjaro 5, 10 or 15 mg or on Ozempic 1 mg. Average starting weight was 93.7 kg (about 207 lb) and average A1C 8.28%.3
| Group | Weight | A1C |
|---|---|---|
| Ozempic 1 mg | −5.7 kg | −1.86 |
| Mounjaro 5 mg | −7.6 kg | −2.01 |
| Mounjaro 10 mg | −9.3 kg | −2.24 |
| Mounjaro 15 mg | −11.2 kg | −2.30 |
Average change at 40 weeks. A1C is in percentage points.1,3
All three Mounjaro doses outperformed Ozempic 1 mg for weight and for A1C. The extra weight loss averaged about 4 lb at 5 mg, 8 lb at 10 mg and 12 lb at 15 mg.3
What the trial could not show
- Ozempic 2 mg was left out. In SUSTAIN FORTE, which compared 2 mg with 1 mg for 40 weeks, weight fell 6.4 kg versus 5.6 kg, a gap that was not statistically significant.2,7
- Nobody took a placebo. In separate trials, weight fell 6.3 to 7.8 kg on Mounjaro versus 1.0 kg on placebo (SURPASS-1, 40 weeks), and 3.8 to 4.7 kg on Ozempic versus 1.2 kg (SUSTAIN 1, 30 weeks).1,2
- It was open-label and paid for by Eli Lilly.
- It ran 40 weeks and included no one without diabetes.
At weight management doses
SURMOUNT-5 tested the same ingredients in 751 adults with obesity and no diabetes. Over 72 weeks, weight fell 20.2% with tirzepatide (10 or 15 mg) and 13.7% with semaglutide (1.7 or 2.4 mg).8 It too was open-label, Lilly-funded and placebo-free, and it left out Wegovy’s newer 7.2 mg dose.9 Those doses belong to Zepbound and Wegovy.
Results vary. Wegovy’s label notes that semaglutide led to less weight reduction when type 2 diabetes was present (9.6%) than when it was not (14.9%).9 No trial can say how much you will lose.
Blood sugar, heart and kidney protection
A1C
Both cut A1C by about two points from a starting level near 8.3%. Mounjaro led at every dose, yet 79% of the Ozempic group still finished under 7%, against 82% to 86% on Mounjaro.1,3
Heart
Each label includes an indication for cutting major cardiovascular events (cardiovascular death, heart attack, stroke) when type 2 diabetes is present: Ozempic for adults who have cardiovascular disease, Mounjaro (since August 2026) for adults at high risk.1,2 Ozempic’s evidence is SUSTAIN 6, where events occurred in 6.6% on Ozempic and 8.9% on placebo.10 Mounjaro’s is SURPASS-CVOT, where it proved no worse than dulaglutide, another GLP-1 drug (12.2% versus 13.1%), and was not proven better.11 The designs differ, so the two results cannot be ranked.
Kidneys
Only Ozempic has a kidney indication, covering chronic kidney disease in people with type 2 diabetes. In the FLOW trial, the main kidney outcome was 24% less likely with Ozempic 1 mg than with placebo.2,12 Mounjaro’s label has none.1
Mounjaro vs Ozempic side effects
Side effects overlap heavily: nausea, diarrhea and vomiting lead both lists. In SURMOUNT-5, most side effects in either group were gastrointestinal, mild to moderate, and tied to dose increases.8 Within SURPASS-2 the rates were:
| Side effect | Mounjaro three doses | Ozempic 1 mg dose |
|---|---|---|
| Nausea | 17 to 22% | 18% |
| Diarrhea | 13 to 16% | 12% |
| Vomiting | 6 to 10% | 8% |
| Serious adverse events | 5 to 7% | 3% |
SURPASS-2, 40 weeks.3
In each label’s placebo-controlled trials, nausea affected 12% to 18% on Mounjaro (placebo 4%) and 15.8% to 20.3% on Ozempic (placebo 6.1%), rising with dose.1,2 Those trials were separate, so they are not a direct comparison.
Warnings found in both labels
Each label opens with a boxed warning on thyroid C-cell tumors, and neither drug should be taken by anyone who has had medullary thyroid carcinoma, has a relative who had it, or has MEN 2. Each also warns of pancreatitis, low blood sugar alongside insulin or a sulfonylurea, kidney harm from dehydration, gallbladder disease and worsening diabetic eye disease.1,2 On November 9, 2026, the FDA said every GLP-1 label must add a warning about a possible risk of NAION, a rare cause of sudden vision loss in one eye.13 See the safety information.
Where they differ
- Birth control pills. Mounjaro may make them less effective. Its label advises a non-oral or added barrier method for 4 weeks after starting and after each dose increase. Ozempic’s has no such instruction.1,2
- Pregnancy planning. Ozempic’s label says to stop at least 2 months before a planned pregnancy. Mounjaro’s gives no waiting period.1,2
More detail: Mounjaro side effects, Ozempic side effects and GLP-1 side effects.
Mounjaro vs Ozempic dosing
Each is a once-weekly shot under the skin that can be given at any hour, with food or without, and each begins at a low dose.1,2 The milligram numbers sit on different scales, so Mounjaro 5 mg is not “five times” Ozempic 1 mg.
| Dosing step | Mounjaro | Ozempic |
|---|---|---|
| First dose | 2.5 mg | 0.25 mg for 4 weeks, then 0.5 mg |
| Stepping up | By 2.5 mg, after 4 weeks or more on a dose, if blood sugar needs it | Up to 1 mg and later 2 mg, after 4 weeks or more on a dose, if blood sugar needs it |
| Top dose | 15 mg weekly | 2 mg weekly |
| Late dose | Inject within 4 days, otherwise skip it | Inject within 5 days, otherwise skip it |
| New weekly day | Keep 3 days or more between doses | Keep 2 days or more between doses |
| Pen | Single-dose pen, one per week | Multi-dose pen with a dial and a fresh needle each time |
From each prescribing information.1,2
Semaglutide can also be taken by mouth: Ozempic tablets (1.5, 4 or 9 mg) are swallowed daily on an empty stomach.14 Tirzepatide is injection-only.1 For full schedules, see Ozempic dosage and Mounjaro dosing.
Mounjaro vs Ozempic cost
When a commercial plan pays for the drug, either one can cost as little as $25 a fill once the maker’s savings program is applied. If you pay cash, Ozempic tends to cost less: $349 a month for most doses, against $499 and up for Mounjaro.5,6 Prices are as of November 2026.
| Your situation | Mounjaro | Ozempic |
|---|---|---|
| Your commercial plan covers it | Mounjaro Savings Card: as low as $25 for a fill of 1 to 3 months | Ozempic savings offer: as low as $25 |
| Your commercial plan does not cover it | Same card: as low as $499 a month | Cash prices in the next row |
| Paying cash | LillyDirect: $499 a month and up | $349 a month, or $499 for 2 mg. New patients: $199 for the first two fills of 0.25 or 0.5 mg, through December 31, 2026 |
| Medicare, Medicaid or other government coverage | Savings card not allowed | Savings offer not allowed |
Lilly and Novo Nordisk, as of November 2026.5,6,15 Lilly’s card expires December 31, 2026 and covers approved uses only, which for Mounjaro means type 2 diabetes.
Coverage decides most of the price. KFF reports that health plans have generally covered these drugs for diabetes, while 18% of large employers said their biggest plan covered GLP-1s for weight loss in 2026.16 Check yours with our GLP-1 insurance checker, or see Mounjaro cost and Ozempic cost.
If your plan covers neither
Ask your provider whether another FDA-approved medication is on your plan’s list. Zealthy providers can also prescribe compounded tirzepatide or semaglutide if they judge it suitable. A compounded drug has no FDA approval: the agency does not review it for safety, effectiveness or quality, and the trial results on this page do not describe it.17
Switching from Ozempic to Mounjaro
You can switch in either direction through your prescriber. Mounjaro’s label has no conversion from semaglutide and one starting dose, 2.5 mg, so a provider sets the new dose and the date.1
- One at a time. Each stimulates the GLP-1 receptor, and the Zepbound and Wegovy labels (same ingredients) advise against combining with another GLP-1 medication.4,9
- Expect a restart. No Ozempic dose maps to a Mounjaro dose, and stomach side effects can return as doses rise.
- Birth control pills. On Mounjaro, use backup contraception for 4 weeks after the first dose and each increase.1
- Insulin or a sulfonylurea. Ask whether that dose should change, since either drug can cause low blood sugar alongside them.1,2
Never bridge a gap with leftover pens, and leave dose changes to your prescriber.
Is Mounjaro better than Ozempic?
On average, Mounjaro brought A1C and weight down further than Ozempic 1 mg in SURPASS-2, and tirzepatide led semaglutide on weight in SURMOUNT-5.3,8 The evidence stops there. It does not cover Ozempic 2 mg, compare heart or kidney outcomes, or predict your response.
| Your situation | Point to raise with a provider |
|---|---|
| You want the largest average drop in A1C and weight | Mounjaro led in SURPASS-2 |
| You have chronic kidney disease | Only Ozempic has a kidney indication |
| You prefer a tablet | Ozempic comes as a daily tablet |
| You take birth control pills | Mounjaro needs backup contraception around dose changes |
| You pay cash | Ozempic costs less at most doses |
| Your plan covers one | Usually the covered one |
| You do not have diabetes | Zepbound or Wegovy, approved for weight management |
How Zealthy fits in
Zealthy does not choose for you. A U.S.-licensed physician or nurse practitioner reviews your online intake and decides which medication, if any, is appropriate. No live appointment is required to start.
- Brand-name prescriptions (Mounjaro, Ozempic, Zepbound, Wegovy) go to your own pharmacy.
- Our insurance coordination team submits prior authorizations. When your plan covers the medication, the copay can be as low as $25 a month. Approval is not guaranteed.
- Compounded semaglutide and tirzepatide are separate options at $199 and $329 a month, or from $106 and $216 a month on a 3-month supply. They are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality.
Medication is not part of the membership fee, which is $39 the first month and $135 a month afterward.
Mounjaro vs Ozempic: common questions
Which causes more weight loss, Mounjaro or Ozempic?
Mounjaro, on average. In SURPASS-2, average losses over 40 weeks were 16.8 to 24.7 lb with Mounjaro and 12.6 lb with Ozempic 1 mg. Ozempic 2 mg was not tested, results vary, and weight loss is not an approved use of either drug.
What dose of Mounjaro is equal to Ozempic 1 mg?
No dose is equivalent. They are different molecules on different scales, and Mounjaro’s label has no conversion from semaglutide. In SURPASS-2, even Mounjaro 5 mg reduced A1C and weight slightly more than Ozempic 1 mg. After a switch, your provider chooses the starting dose.
Switching from Ozempic to Mounjaro: how does it work?
Your prescriber stops Ozempic and writes a new prescription. No official conversion exists, so the provider picks your starting dose and first injection date. Mounjaro’s label starts at 2.5 mg. If you take birth control pills, plan on a backup method.
Is it safe to use Ozempic and Mounjaro at the same time?
No, they are prescribed one at a time. Each stimulates the GLP-1 receptor, and the labels for Zepbound and Wegovy, which contain the same ingredients, say they are not recommended with another GLP-1 medication. Your provider will stop one before starting the other.
Does Mounjaro cause more side effects than Ozempic?
Not by much. In SURPASS-2, nausea affected 17% to 22% on Mounjaro and 18% on Ozempic 1 mg, diarrhea 13% to 16% and 12%, and vomiting 6% to 10% and 8%. Serious adverse events were reported in 5% to 7% and 3%.
Which costs less without insurance, Mounjaro or Ozempic?
Ozempic, usually. As of November 2026, Novo Nordisk charges cash payers $349 a month for 0.25, 0.5 and 1 mg and $499 for 2 mg, while Lilly’s cash price for Mounjaro starts at $499. With covered commercial insurance, either savings program can lower a fill to $25.
Can you get Mounjaro or Ozempic for weight loss without diabetes?
Not as an approved use. The FDA has approved both only for type 2 diabetes, so prescribing either for weight alone is off-label, and Lilly’s savings card does not apply. Zepbound and Wegovy contain the same ingredients and are approved for weight management.
Does insurance cover Mounjaro and Ozempic?
Often for type 2 diabetes, much less often for weight loss alone. Your plan may require prior authorization, which Zealthy’s coordination team submits for members. When your plan covers the medication, the copay can be as low as $25 a month.
Important safety information for Mounjaro and Ozempic
A summary of the prescribing information for both.1,2 It does not replace either label.
Boxed warning: risk of thyroid C-cell tumors
In rodents, tirzepatide and semaglutide each caused thyroid C-cell tumors. It is not known whether Mounjaro or Ozempic causes them, including medullary thyroid carcinoma (MTC), in people. Do not use either if you or a family member has had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a neck lump, lasting hoarseness, trouble swallowing or shortness of breath.
Do not use either medication if
You or a family member has had MTC, you have MEN 2, or you have had a serious allergic reaction to tirzepatide, semaglutide or another ingredient.
Tell your provider if you
- Have had pancreas problems, diabetic retinopathy or severe stomach problems such as gastroparesis.
- Take insulin, a sulfonylurea or birth control pills.
- Have surgery or a procedure with anesthesia or deep sedation planned.
- Are pregnant, breastfeeding or planning a pregnancy.
Serious side effects
Pancreatitis, low blood sugar when used with insulin or a sulfonylurea, serious allergic reactions, dehydration leading to kidney problems, severe stomach problems, vision changes including diabetic retinopathy complications, gallbladder problems, and food or liquid entering the lungs during anesthesia or deep sedation. Get medical help right away for severe stomach pain that will not go away, swelling of the face or throat, or trouble breathing.
The FDA said on November 9, 2026 that all GLP-1 labels must add a warning about a possible risk of NAION. Seek care right away for sudden vision loss in one eye.13
Most common side effects
Mounjaro: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and stomach pain. Ozempic: nausea, vomiting, diarrhea, stomach pain and constipation. Report side effects to the FDA at 1-800-FDA-1088.
Sources
- Mounjaro (tirzepatide) injection Prescribing Information. Eli Lilly and Company. Revised August 2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
- Ozempic (semaglutide) injection Prescribing Information. Novo Nordisk. Revised May 2026. https://www.novo-pi.com/ozempic.pdf
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Zepbound (tirzepatide) injection Prescribing Information. Eli Lilly and Company. Revised August 2026. https://pi.lilly.com/us/zepbound-uspi.pdf
- Eli Lilly and Company. Mounjaro through LillyDirect. https://www.lilly.com/lillydirect/medicines/mounjaro
- Novo Nordisk. Ozempic cost and insurance coverage. https://www.ozempic.com/savings-and-resources/save-on-ozempic.html
- Frías JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE). Lancet Diabetes Endocrinol. 2021;9(9):563-574. https://pubmed.ncbi.nlm.nih.gov/34293304/
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
- Wegovy (semaglutide) injection and tablets Prescribing Information. Novo Nordisk. Revised June 2026. https://www.novo-pi.com/wegovy.pdf
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. https://pubmed.ncbi.nlm.nih.gov/27633186/
- Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med. 2025;393(24):2409-2420. https://pubmed.ncbi.nlm.nih.gov/41406444/
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. https://pubmed.ncbi.nlm.nih.gov/38785209/
- FDA. FDA requires safety labeling changes for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) due to potential increased risk of rare but serious eye condition. Drug Safety Communication, November 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
- Rybelsus (semaglutide) tablets and Ozempic (semaglutide) tablets Prescribing Information. Novo Nordisk. Revised January 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051Orig1s030lbl.pdf
- Eli Lilly and Company. Mounjaro savings and support, including Savings Card terms. https://mounjaro.lilly.com/savings-resources
- KFF. 2026 Employer Health Benefits Survey. https://www.kff.org/health-costs/2026-employer-health-benefits-survey/
- FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Find out which GLP-1 a licensed provider would choose for you
Answer a few health questions online. A licensed provider reviews them, and membership starts at $39 for the first month.

Two strong medications, one decision made with a provider
Your intake goes to a U.S.-licensed physician or nurse practitioner, who looks at your blood sugar history, heart and kidney health, current prescriptions and coverage before recommending anything.
The medical information on this page is reviewed by the Zealthy care team against FDA prescribing information and published clinical trials. It is general education, not personal medical advice.
What Zealthy members say
One of the things I appreciate most about semaglutide is its convenience. The once-weekly dosing schedule has made it incredibly easy to integrate into my routine. It's a relief to know that I don't have to worry about multiple daily injections or complicated medication schedules.
I started semaglutide at the recommendation of my Zealthy provider and I'm so happy with that decision. I signed up for their weight loss program and they've been giving me everything I need to make better lifestyle choices to get results that last. And the program's super affordable. 10/10 I can't recommend this enough.
Getting support a weight loss program has always been hard for me. I had been wanting to start one with a medication component for a while and Zealthy was the first one that made it easy for me with weight loss shots sent to me. They made it SO affordable and the medical team is great.
Since I started, I have already lost 35 pounds and feel so much better. My doctor also helped me get a prescription for ozempic and he is always available to answer my questions in the message portal. This made me feel a lot more comfortable and excited to lose weight.
The weight loss program is fantastic. Everyone has been so helpful and has helped me feel much more excited about the process. I was nervous to see my weight loss treatment plan, since I have done programs in the past, but they always wanted me to make drastic changes. I mentioned all of this to my weight loss coach and she was very understanding and made a customized plan for me.
I've been a member for 6 months now and have received all my medication every 3 months. Everyone has been so helpful and my care team is always available to help me!
Individual results may vary. These are the experiences of Zealthy members and are not a guarantee of any outcome. Medication is prescribed only when a licensed provider finds it appropriate.
GLP-1 medications Zealthy providers can prescribe
Brand-name or compounded, a licensed provider decides what fits your health history. Our insurance team handles the prior authorization paperwork for brand-name medication.
Zepbound®
Tirzepatide, FDA-approved for weight management and for sleep apnea in adults with obesity.
Zepbound cost, savings card and side effects →Wegovy®
Semaglutide, FDA-approved for weight management, as a weekly injection or a daily pill.
Wegovy pill, cost and side effects →Mounjaro®
Tirzepatide, FDA-approved for type 2 diabetes. The same ingredient as Zepbound.
Mounjaro doses and savings card →Ozempic®
Semaglutide, FDA-approved for type 2 diabetes. Weight loss is an off-label use.
Ozempic side effects and cost →Compounded semaglutide
$199 a month, or from $106 a month on a 3-month supply, shipping included. Not FDA-approved.
Semaglutide cost and dosing →Compounded tirzepatide
$329 a month, or from $216 a month on a 3-month supply, shipping included. Not FDA-approved.
Tirzepatide dosage and cost →Compounded medications are prepared by a partner pharmacy for an individual prescription. They are not FDA-approved, which means the FDA has not reviewed them for safety, effectiveness or quality. Zealthy membership ($39 for the first month, then $135 a month) is billed separately from medication. A prescription is written only if a licensed provider finds it appropriate.